About Lymphoma | Advocacy | Art | CAM | Clinical trials | Doctors - Experts - Centers | Guidelines at Diagnosis | News
Risk Factors | Side Effects | Statistics | Support | Symptoms | Tests | Treatments | Types of Lymphoma

Search Site         Guidelines at Diagnosis | About Clinical Trials            How to Help!

Patients Against Lymphoma

 

Radioimmunotherapy: | Bexxar Info | Zevalin Info | Bexxar vs Zevalin | Other Agents

Treatments > Radioimmunotherapy > Other Radioimmunotherapy Agents

Last update: 12/18/2009

Radiolabeled antibodies combine Monoclonal antibodies with radioactive agents. The goal of this combination is to bring additional killing power (radiation) to the malignant cells and fewer normal cells.

 


Related Topics:

News: 
  • NEW Hodgkin's treatment destroys tumors with antibody linked to radioactive particle - CHT25 http://bit.ly/CHT25
  • Updated Phase II Results With Radiolabeled Epratuzumab in Non-Hodgkin's Lymphoma drugs.com 

    The overall objective response rate (partial and complete responses) in 62 evaluable patients was 64%, with 49% of patients having a complete response. Both the objective and complete response rates appear to correlate with cumulative doses. In 16 patients unresponsive to last therapy, 75% responded to Y-90 epratuzumab tetraxetan with 56% complete responses. More importantly, responses were seen across all different types of NHL.
  • Anti-cd22 RIT:  Fractionated Radioimmunotherapy (RIT) With (90)Y-epratuzumab in Non-Hodgkin's Lymphoma Appears Safe and Active in a Phase I/II Study - earthtimes.org

    Current RAIT treatments for NHL such as tositumomab and ibritumomab tiuxetan are radiolabeled murine antibodies targeting the CD20 antigen on the surface of mature B-cells and B-cell tumors as expressed by NHL cells. Immunomedics' epratuzumab is a humanized monoclonal antibody that targets the CD22 antigen on B-cells, including malignant B-cells. 

    The internalizing property of epratuzumab is believed to be well suited for delivering radiation from the potent radioisotope, yttrium-90, selectively and locally to lymphoma cells that express the CD22 antigen. Moreover, because epratuzumab is humanized, it is argued that the new RAIT can be administered to patients repeatedly in smaller doses. Researchers found that splitting the dose over two or three fractions made it tolerable to patients while delivering higher radioactivity to tumor cells.

 

Lym-1

iodine I 131 monoclonal antibody for HLA-Dr10  positive b-cell lymphomas

Condition: Recurrent NHL

Related PubMed Abstracts

 

Abstracts & Links:

  • Milestones in the development of Lym-1 therapy. Hybridoma. 1999 Feb;18(1):1-11. Review. PMID: 10211782 - PubMed
  • Oncolym - Lymphoma Inf Net | LYM-1 - UCDMC | (Experimental) 
    "Clinical trial using the anti-lymphoma Lym-1 antibody, radiolabeled with Yttrium-90 (Y-90) are in progress at UCDMC. No hospitalization is needed and Y-90 can deliver high energy radiation to the lymphoma." The Lym-1 antibody attaches to is the HLA-Dr10 protein, a cell surface marker present on over 80% of lymphoma cells. (Phase II/III?)
  • Increased survival associated with radiolabeled Lym-1 therapy for non-Hodgkin's lymphoma and chronic lymphocytic leukemia.
    Cancer. 1997 Dec 15;80(12 Suppl):2706-11. PMID: 9406728 - PubMed
Yttrium-90 Radiolabeled Humanized Anti-Tac and Calcium-DTPA

Condition: T-cell lymphoma

Abstracts & Links:

  • Rapid and specific uptake of anti-Tac disulfide-stabilized Fv by interleukin-2 receptor-bearing tumors. Cancer Res. 1995 Jan 15;55(2):318-23. PMID: 7812965 - PubMed
LR131 - Radiolabeled BLyS protein

For BLyS expressing b-cell lymphomas

Abstracts & Links:

  • Radiolabeled BLyS protein (LR131) inhibits neoplastic B cell growth in vivo Year: 2002 Abstract No: 39
Other
Abstracts & Links:
 
  • Fractionated Radioimmunotherapy (RIT) With (90)Y-epratuzumab in Non-Hodgkin's Lymphoma Appears Safe and Active in a Phase I/II Study - earthtimes.org

    Current RAIT treatments for NHL such as tositumomab and ibritumomab tiuxetan are radiolabeled murine antibodies targeting the CD20 antigen on the surface of mature B-cells and B-cell tumors as expressed by NHL cells. Immunomedics' epratuzumab is a humanized monoclonal antibody that targets the CD22 antigen on B-cells, including malignant B-cells. The internalizing property of epratuzumab is believed to be well suited for delivering radiation from the potent radioisotope, yttrium-90, selectively and locally to lymphoma cells that express the CD22 antigen. Moreover, because epratuzumab is humanized, it is argued that the new RAIT can be administered to patients repeatedly in smaller doses. Researchers found that splitting the dose over two or three fractions made it tolerable to patients while delivering higher radioactivity to tumor cells.
  • LymphoCide Y-90  (CD 22 targeted)

    Yttrium-90-labeled humanized antibody targeting CD22 receptors in B-cell lymphomas. Primary use is for the treatment of indolent and aggressive NHLs. Every year there are 56,000 newly diagnosed cases and 25,000 deaths. It is currently in Phase I clinical trials. 
  • 90Y-DOTA-hLL2: an agent for radioimmunotherapy of non-Hodgkin's lymphoma. J Nucl Med. 2003 Jan;44(1):77-84. PMID: 12515879 - PubMed
  • CLEARING AGENT COULD ENHANCE RADIOLABELED TREATMENTS: A phase I study evaluating the pharmacokinetics of anti-CD20 fusion protein, synthetic clearing agent and 90yttrium DOTA-biotin. Year: 2002 Abstract No: 9
  • Pretarget - NeoRx (Experimental) 
    Reduces exposure of normal tissue by using a 2-step process.  The first step delivers a non-radioactive antibody with an extra receptor (targeting agent). The radioactive agent is then delivered to the tumor via a small molecule that binds to the   targeting agent but is otherwise innocuously excreted from the body. (Phase II)
 
Disclaimer:  The information on Lymphomation.org is not intended to be a substitute for 
professional medical advice or to replace your relationship with a physician.
For all medical concerns,  you should always consult your doctor. 
Patients Against Lymphoma, Copyright 2004,  All Rights Reserved.